Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lung cancer drug under Real-World watch in south korea

NCT ID NCT05703516

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 16, 2026 · Last updated Jun 17, 2026 · Updated 2 times

Summary

This study is tracking how safe and effective the drug Tabrecta (Capmatinib) is for people with a specific type of lung cancer (non-small-cell lung cancer with an exon 14 skipping mutation). About 44 participants in South Korea will receive the drug as part of their normal care, and researchers will monitor side effects and tumor response. The goal is to confirm the drug works well in everyday practice, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    RECRUITING

    Suwon, Gyeonggi-do, 16499, South Korea

  • Novartis Investigative Site

    RECRUITING

    Incheon, Korea, 405 760, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 02447, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 602-030, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daejeon, 302-241, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CARCINOMA